Editas Medicine Raises $120M

What does Editas Medicine do?

Editas Medicine, is a leading genome editing company. The company is engaged in finding and developing a novel class of genome editing therapeutics. Its mission is translating the genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification for treating the underlying cause of a broad range of diseases at the gene level. Editas Medicine has generated substantial patent fillings and can access intellectual property covering foundation genome editing technologies, emblements and all the essential advancements which will uniquely enable the company for translating early finding into viable therapeutic products.

How much Editas Medicine was funded?

Editas Medicine has raised  $120M in Series B funding on August 10, 2015 from Deerfield Management, Fidelity Management & Research company, Flagship Ventures, Third Rock Ventures, Polaris Partners and Partner Innovation Fund.

Previous funding

$43M in Series A funding on November 25, 2013 from Flagship Ventures (Lead) Partner: Douglas G. Cole, Third Rock Ventures (Lead) Partner: Alexis Borisy, Polaris Partners (Lead) Partner: Terrance G. McGuire and Partners Innovation Fund

 What is next for Editas Medicine?

The latest funding of $120 M comes in a highly oversubscribed Series B private financing. It assembles a many leading public and private investors. The company is translating the promise of CAS9/CRISPR into a new class of transformative genomic medicines for treating a broad range of diseases by enabling corrective and precise molecular modifications for treating diseases at the gene level. With the finances, the company has a strong foundation which to broadly develop its genome editing platform and advance multiple new therapies towards clinical trials.

More about Editas Medicine

Editas Medicine was founed in 2013 by J. Keith Joung, Jennifer A. Doudna, George Church, and Feng Zhang. It has its headquarters in Cambridge, MA. The company is unlocking the promise of Genome editing for delivering life changing medicines.